The inhibitory effect of IRE1α inhibitor 4 μ8c on IRE1α has a certain inhibitory effect on the progress of non-small cell lung cancer, and can be combined with nivolumab to strengthen the effect. Here, ERN1 is linked to non-small cell lung carcinoma.